Published in Hum Mol Genet on October 01, 1997
Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A (2003) 2.65
Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression. J Biomed Sci (2004) 2.11
Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. J Neurosci (2006) 1.80
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest (2004) 1.73
SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet (2010) 1.30
Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat (2013) 1.23
Spinal muscular atrophy and a model for survival of motor neuron protein function in axonal ribonucleoprotein complexes. Results Probl Cell Differ (2009) 1.17
Induction of full-length survival motor neuron by polyphenol botanical compounds. Hum Genet (2007) 1.06
Axonal-SMN (a-SMN), a protein isoform of the survival motor neuron gene, is specifically involved in axonogenesis. Proc Natl Acad Sci U S A (2007) 0.99
The promoters of the survival motor neuron gene (SMN) and its copy (SMNc) share common regulatory elements. Am J Hum Genet (1999) 0.94
Heterogeneity of subcellular localization and electrophoretic mobility of survival motor neuron (SMN) protein in mammalian neural cells and tissues. Proc Natl Acad Sci U S A (1998) 0.92
Reduced levels of survival motor neuron protein leads to aberrant motoneuron growth in a Xenopus model of muscular atrophy. Neurogenetics (2009) 0.91
Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice. PLoS One (2013) 0.90
Spinal muscular atrophy: untangling the knot? J Med Genet (1999) 0.88
Spinal muscular atrophy: journeying from bench to bedside. Neurotherapeutics (2014) 0.87
Spinal Muscular Atrophy Therapeutics: Where do we Stand? Neurotherapeutics (2015) 0.86
Characterization of the survival motor neuron (SMN) promoter provides evidence for complex combinatorial regulation in undifferentiated and differentiated P19 cells. Biochem J (2005) 0.84
Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol Exp Neurol (2015) 0.84
Utility of survival motor neuron ELISA for spinal muscular atrophy clinical and preclinical analyses. PLoS One (2011) 0.84
Cell-specific survival motor neuron gene expression during human development of the central nervous system: implications for the pathogenesis of spinal muscular atrophy. Am J Pathol (1998) 0.84
Deletion analysis of SMN1 and NAIP genes in Southern Chinese children with spinal muscular atrophy. J Zhejiang Univ Sci B (2009) 0.82
Bone health and associated metabolic complications in neuromuscular diseases. Phys Med Rehabil Clin N Am (2012) 0.80
Identification and characterization of the porcine (Sus scrofa) survival motor neuron (SMN1) gene: an animal model for therapeutic studies. Dev Dyn (2008) 0.79
Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy. Neurotherapeutics (2013) 0.78
Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy. Proc Natl Acad Sci U S A (2017) 0.78
Different Stability and Proteasome-Mediated Degradation Rate of SMN Protein Isoforms. PLoS One (2015) 0.77
The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy. Neuron (2016) 0.76
Radiographic and Respiratory Effects of Growing Rods in Children With Spinal Muscular Atrophy. J Pediatr Orthop (2016) 0.75
Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 17.41
Multi-system neurological disease is common in patients with OPA1 mutations. Brain (2010) 5.37
Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet (2001) 5.09
Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med (1989) 4.87
Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell (1998) 4.41
Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet (1998) 3.86
Mitochondrial myopathies. Ann Neurol (1985) 3.81
Haplotype and phylogenetic analyses suggest that one European-specific mtDNA background plays a role in the expression of Leber hereditary optic neuropathy by increasing the penetrance of the primary mutations 11778 and 14484. Am J Hum Genet (1997) 3.48
Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency. Am J Hum Genet (1998) 3.08
A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science (1989) 3.02
De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science (1994) 2.87
Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science (2000) 2.66
Clinical and molecular findings in children with complex I deficiency. Biochim Biophys Acta (2004) 2.52
Cytochrome c oxidase deficiency in Leigh syndrome. Ann Neurol (1987) 2.20
Identification of the gene encoding the human mitochondrial RNA polymerase (h-mtRPOL) by cyberscreening of the Expressed Sequence Tags database. Hum Mol Genet (1997) 2.15
Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations. Neurology (2005) 2.01
Evidence that nebulin is a protein-ruler in muscle thin filaments. FEBS Lett (1991) 1.87
Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology (1986) 1.78
Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis (2008) 1.77
Characterization of SURF-1 expression and Surf-1p function in normal and disease conditions. Hum Mol Genet (1999) 1.66
Loss-of-function mutations of SURF-1 are specifically associated with Leigh syndrome with cytochrome c oxidase deficiency. Ann Neurol (1999) 1.63
Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet (2002) 1.56
Maternally inherited hearing loss, ataxia and myoclonus associated with a novel point mutation in mitochondrial tRNASer(UCN) gene. Hum Mol Genet (1995) 1.54
Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells. Mitochondrion (2012) 1.49
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Mutations of ANT1, Twinkle, and POLG1 in sporadic progressive external ophthalmoplegia (PEO). Neurology (2003) 1.43
Single-stranded-DNA-binding proteins from human mitochondria and Escherichia coli have analogous physicochemical properties. Eur J Biochem (1994) 1.41
GJA12 mutations in children with recessive hypomyelinating leukoencephalopathy. Neurology (2006) 1.39
Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann Neurol (1998) 1.37
An autosomal locus predisposing to deletions of mitochondrial DNA. Nat Genet (1995) 1.36
Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord. Hum Mol Genet (2000) 1.35
MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology (1988) 1.34
Subunit Va of human and bovine cytochrome c oxidase is highly conserved. Gene (1988) 1.33
Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol (1989) 1.28
GABAB receptor protein and mRNA distribution in rat spinal cord and dorsal root ganglia. Eur J Neurosci (2000) 1.27
Fatal infantile cytochrome c oxidase deficiency: decrease of immunologically detectable enzyme in muscle. Neurology (1985) 1.25
Genetic analysis of the immunity region of phage-plasmid P4. Mol Microbiol (1992) 1.21
Shy1p occurs in a high molecular weight complex and is required for efficient assembly of cytochrome c oxidase in yeast. FEBS Lett (2001) 1.20
Nuclear DNA origin of cytochrome c oxidase deficiency in Leigh's syndrome: genetic evidence based on patient's-derived rho degrees transformants. Hum Mol Genet (1995) 1.20
Superoxide dismutase gene mutations in Italian patients with familial and sporadic amyotrophic lateral sclerosis: identification of three novel missense mutations. Neuromuscul Disord (2001) 1.18
A nonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome. Hum Mol Genet (2001) 1.18
Identification of new mutations in the ETHE1 gene in a cohort of 14 patients presenting with ethylmalonic encephalopathy. J Med Genet (2008) 1.16
Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology (1993) 1.16
Complex I deficiency is associated with 3243G:C mitochondrial DNA in osteosarcoma cell cybrids. Hum Mol Genet (1996) 1.16
Transcriptional regulation of furA and katG upon oxidative stress in Mycobacterium smegmatis. J Bacteriol (2001) 1.15
A novel frameshift mutation of the mtDNA COIII gene leads to impaired assembly of cytochrome c oxidase in a patient affected by Leigh-like syndrome. Hum Mol Genet (2000) 1.13
Cloning of human and rat cDNAs encoding the mitochondrial single-stranded DNA-binding protein (SSB). Gene (1993) 1.12
A single cell complementation class is common to several cases of cytochrome c oxidase-defective Leigh's syndrome. Hum Mol Genet (1997) 1.11
Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology (1990) 1.11
Order of six loci at 2q24-q31 and orientation of the HOXD locus. Genomics (1994) 1.10
Dominantly inherited mitochondrial myopathy with multiple deletions of mitochondrial DNA: clinical, morphologic, and biochemical studies. Neurology (1991) 1.10
Evidence for an excess of B→D*τ(-)ν(τ) decays. Phys Rev Lett (2012) 1.10
Observation of time-reversal violation in the B0 meson system. Phys Rev Lett (2012) 1.09
A novel missense adenine nucleotide translocator-1 gene mutation in a Greek adPEO family. Neurology (2001) 1.08
Precise measurement of the e+e- --> pi+pi-(gamma) cross section with the initial state radiation method at BABAR. Phys Rev Lett (2009) 1.07
The plasmid status of satellite bacteriophage P4. Plasmid (2001) 1.07
Disorders from perturbations of nuclear-mitochondrial intergenomic cross-talk. J Intern Med (2009) 1.07
Collated mutations in mitochondrial DNA (mtDNA) depletion syndrome (excluding the mitochondrial gamma polymerase, POLG1). Biochim Biophys Acta (2009) 1.06
Mitochondrial myopathies. J Inherit Metab Dis (1987) 1.06
Hearing impairment and neurological dysfunction associated with a mutation in the mitochondrial tRNASer(UCN) gene. Eur J Hum Genet (1999) 1.05
Measurement of |V(cb)| and the form-factor slope in B --> Dl- nu(l) decays in events tagged by a fully reconstructed B meson. Phys Rev Lett (2010) 1.05
Defective respiratory capacity and mitochondrial protein synthesis in transformant cybrids harboring the tRNA(Leu(UUR)) mutation associated with maternally inherited myopathy and cardiomyopathy. J Clin Invest (1994) 1.05
Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum Mol Genet (2000) 1.05
Mitochondrial disease associated with the T8993G mutation of the mitochondrial ATPase 6 gene: a clinical, biochemical, and molecular study in six families. J Neurol Neurosurg Psychiatry (1997) 1.05
ETHE1 mutations are specific to ethylmalonic encephalopathy. J Med Genet (2005) 1.04
Benign reversible muscle cytochrome c oxidase deficiency: a second case. Neurology (1987) 1.04
Control of transcription termination by an RNA factor in bacteriophage P4 immunity: identification of the target sites. J Bacteriol (1995) 1.04
Cytochrome c oxidase deficiency. Biochem Soc Trans (1985) 1.02
Novel mutations in COX15 in a long surviving Leigh syndrome patient with cytochrome c oxidase deficiency. J Med Genet (2005) 1.01
Neuromuscular syndrome associated with the 3291T-->C mutation of mitochondrial DNA: a second case. Neuromuscul Disord (2000) 1.01
Is nebulin the defective gene product in Duchenne muscular dystrophy? N Engl J Med (1987) 1.01
Genotype to phenotype correlations in mitochondrial encephalomyopathies associated with the A3243G mutation of mitochondrial DNA. J Neurol (1995) 1.00
X-inactivation patterns in female Leber's hereditary optic neuropathy patients do not support a strong X-linked determinant. Am J Med Genet (1996) 1.00
Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial genome. J Med Genet (2004) 0.97
A novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients. Ann Neurol (2001) 0.97
EFNS guidelines on the molecular diagnosis of mitochondrial disorders. Eur J Neurol (2009) 0.97
POLG1 in idiopathic Parkinson disease. Neurology (2006) 0.96
Search for the rare leptonic decay B--->tau-nutau. Phys Rev Lett (2005) 0.96
Mutations in the SURF1 gene associated with Leigh syndrome and cytochrome C oxidase deficiency. Hum Mutat (2001) 0.95
Myofibrillar-protein isoforms and sarcoplasmic-reticulum Ca2+-transport activity of single human muscle fibres. Biochem J (1984) 0.94
Novel heteroplasmic mtDNA mutation in a family with heterogeneous clinical presentations. Ann Neurol (2002) 0.94
Geometrical and electronic structure variability of the sugar-phosphate backbone in nucleic acids. J Phys Chem B (2008) 0.93
Fulminant Leigh syndrome and sudden unexpected death in a family with the T9176C mutation of the mitochondrial ATPase 6 gene. J Inherit Metab Dis (1998) 0.93
Generation of a selective 5-HT3B subunit-recognising polyclonal antibody; identification of immunoreactive cells in rat hippocampus. Neuropharmacology (2001) 0.93
EFNS guidelines for the molecular diagnosis of neurogenetic disorders: motoneuron, peripheral nerve and muscle disorders. Eur J Neurol (2011) 0.93
Demonstration and characterization of anti-human mitochondria autoantibodies in idiopathic hypoparathyroidism and in other conditions. Clin Exp Immunol (1985) 0.92
Epileptic phenotypes associated with mitochondrial disorders. Neurology (2001) 0.92
EFNS guidelines on the molecular diagnosis of ataxias and spastic paraplegias. Eur J Neurol (2009) 0.91
EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. Second of two parts. Eur J Neurol (2001) 0.91
Further pitfalls in the diagnosis of mtDNA mutations: homoplasmic mt-tRNA mutations. J Med Genet (2008) 0.90
EFNS guidelines on the molecular diagnosis of neurogenetic disorders: general issues, Huntington's disease, Parkinson's disease and dystonias. Eur J Neurol (2009) 0.90
Separation of intact pyruvate dehydrogenase complex using blue native agarose gel electrophoresis. Electrophoresis (2000) 0.90
Cytochrome oxidase deficiency: clinical and biochemical heterogeneity. Ann N Y Acad Sci (1986) 0.90
Molecular phenotype of the np 7472 deafness-associated mitochondrial mutation in osteosarcoma cell cybrids. Hum Mol Genet (1999) 0.90
Ultrastructural analysis of extraocular muscle in chronic progressive external ophthalmoplegia. Arch Ophthalmol (2000) 0.89
Fatal infantile mitochondrial myopathy and renal dysfunction caused by cytochrome c oxidase deficiency: immunological studies in a new patient. Ann Neurol (1985) 0.88
Analysis of the trinucleotide CAG repeat from the human mitochondrial DNA polymerase gene in healthy and diseased individuals. Eur J Hum Genet (1999) 0.88